Lyra Therapeutics (LYRA) Invested Capital (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed Invested Capital for 5 consecutive years, with -$4.3 million as the latest value for Q3 2025.
- On a quarterly basis, Invested Capital fell 120.99% to -$4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.3 million, a 120.99% decrease, with the full-year FY2024 number at $11.6 million, down 87.03% from a year prior.
- Invested Capital was -$4.3 million for Q3 2025 at Lyra Therapeutics, down from $1.6 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $106.2 million in Q2 2022 to a low of -$4.3 million in Q3 2025.
- A 5-year average of $52.1 million and a median of $57.5 million in 2021 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: soared 184.18% in 2023, then plummeted 120.99% in 2025.
- Lyra Therapeutics' Invested Capital stood at $34.3 million in 2021, then skyrocketed by 135.32% to $80.8 million in 2022, then increased by 10.73% to $89.4 million in 2023, then crashed by 87.03% to $11.6 million in 2024, then tumbled by 137.33% to -$4.3 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Invested Capital are -$4.3 million (Q3 2025), $1.6 million (Q2 2025), and $3.9 million (Q1 2025).